Literature DB >> 26473676

Evaluation of the Protection Efficacy of a Serotype 1 Marek's Disease Virus-Vectored Bivalent Vaccine Against Infectious Laryngotracheitis and Marek's Disease.

Isabel M Gimeno1, Aneg L Cortes1, Nik M Faiz1, Byron A Hernandez-Ortiz1, James S Guy1, Henry D Hunt2, Robert F Silva2.   

Abstract

Laryngotracheitis (LT) is a highly contagious respiratory disease of chickens that produces significant economic losses to the poultry industry. Traditionally, LT has been controlled by administration of modified live vaccines. In recent years, the use of recombinant DNA-derived vaccines using turkey herpesvirus (HVT) and fowlpox virus has expanded, as they protect not only against the vector used but also against LT. However, HVT-based vaccines confer limited protection against challenge, with emergent very virulent plus Marek's disease virus (vv+MDV). Serotype 1 vaccines have been proven to be the most efficient against vv+MDV. In particular, deletion of oncogene MEQ from the oncogenic vvMDV strain Md5 (BACδMEQ) resulted in a very efficient vaccine against vv+MDV. In this work, we have developed two recombinant vaccines against MD and LT by using BACδMEQ as a vector that carries either the LT virus (LTV) gene glycoprotein B (gB; BACΔMEQ-gB) or LTV gene glycoprotein J (gJ; BACδMEQ-gJ). We have evaluated the protection that these recombinant vaccines confer against MD and LT challenge when administered alone or in combination. Our results demonstrated that both bivalent vaccines (BACΔMEQ-gB and BACδMEQ-gJ) replicated in chickens and were safe to use in commercial meat-type chickens bearing maternal antibodies against MDV. BACΔMEQ-gB protected as well as a commercial recombinant (r)HVT-LT vaccine against challenge with LTV. However, BACδMEQ-gJ did not protect adequately against LT challenge or increase protection conferred by BACΔMEQ-gB when administered in combination. On the other hand, both BACΔMEQ-gB and BACδMEQ-gJ, administered alone or in combination, protected better against an early challenge with vv+MDV strain 648A than commercial strains of rHVT-LT or CVI988. Our results open a new avenue in the development of recombinant vaccines by using serotype 1 MDV as vectors.

Entities:  

Keywords:  Marek's disease; avian; control; herpesvirus; laryngotracheitis; poultry; vaccine

Mesh:

Substances:

Year:  2015        PMID: 26473676     DOI: 10.1637/10966-103014-Reg

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  3 in total

1.  Investigation of Marek's disease virus from chickens in central Ethiopia.

Authors:  Berhan Demeke; Shiferaw Jenberie; Biruk Tesfaye; Gelagay Ayelet; Martha Yami; Charles Euloge Lamien; Esayas Gelaye
Journal:  Trop Anim Health Prod       Date:  2016-12-14       Impact factor: 1.559

Review 2.  Vaccines against Major Poultry Viral Diseases: Strategies to Improve the Breadth and Protective Efficacy.

Authors:  Rajamanonmani Ravikumar; Janlin Chan; Mookkan Prabakaran
Journal:  Viruses       Date:  2022-05-31       Impact factor: 5.818

3.  Infectious laryngotracheitis: Etiology, epidemiology, pathobiology, and advances in diagnosis and control - a comprehensive review.

Authors:  Vasudevan Gowthaman; Sachin Kumar; Monika Koul; Urmil Dave; T R Gopala Krishna Murthy; Palanivelu Munuswamy; Ruchi Tiwari; Kumaragurubaran Karthik; Kuldeep Dhama; Izabela Michalak; Sunil K Joshi
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.